Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Contemporary Diagnosis and Management of Prostate Cancer (2nd Edition)
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Contemporary Diagnosis and Management of Prostate Cancer (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 22 August 2026 | Viewed by 1427

Special Issue Editor

Prof. Dr. Thomas Jang

E-Mail Website
Guest Editor
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
Interests: upper tract urothelial cancer; kidney cancer; prostate cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue, “Contemporary Diagnosis and Management of Prostate Cancer”.

We are pleased to announce this upcoming Special Issue of Cancers, "Contemporary Diagnosis and Management of Prostate Cancer (2nd Edition)". Prostate cancer is one of the most common cancers in men, and advancements in diagnosis and treatment have greatly influenced patient outcomes. This Special Issue will provide a comprehensive overview of the latest developments in this field, covering various aspects of prostate cancer diagnosis and management. We invite the submission of original research articles and reviews that cover aspects of prostate cancer including, but not limited to, the following:

  1. Contemporary diagnosis and staging of prostate cancer (focusing on biomarkers, imaging, and biopsy techniques);
  2. Active surveillance of prostate cancer (focusing on patient selection and outcomes);
  3. Radical prostatectomy for clinically localized and locally advanced prostate cancer (focusing on open vs. robotic-assisted laparoscopic radical prostatectomy, patient selection, surgical techniques, and patient outcomes);
  4. Radiation therapy for clinically localized and locally advanced prostate cancer (focusing on IMRT, proton beam therapy, brachytherapy, patient selection, and patient outcomes);
  5. Adjuvant and salvage therapies for high-risk and/or recurrent prostate cancer following radical prostatectomy.

All submitted articles will undergo a rigorous peer-review process to ensure that our Special Issue is of the highest scientific quality and relevance. We encourage contributions from researchers, clinicians, and experts in the fields of urology and prostate cancer.

By consolidating the latest research findings and clinical experiences, we aim to enhance our understanding of radical prostatectomy and improve patient outcomes. We believe that your valuable contributions will significantly contribute to the success of this Special Issue.

If you have any questions or require further information or assistance, please do not hesitate to reach out to us. We are here to support and facilitate your participation in this Special Issue.

We look forward to receiving your submissions. 

Prof. Dr. Thomas Jang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • diagnosis
  • management
  • radical prostatectomy
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 782 KB  
Article
Focal Therapy Using High-Intensity Focused Ultrasound for Low- and Intermediate-Risk Prostate Cancer: Results from a Prospective, Multicenter Feasibility Trial
by Gabor Rosta, Simon Turba, Dong-Ho Mun, Azad Shehab, Leon Saciri, Paul F. Engelhardt, Patricia Weisz, Claus Riedl, Ghazal Ameli, Stephan Doblhammer and Harun Fajkovic
Cancers 2025, 17(21), 3429; https://doi.org/10.3390/cancers17213429 - 25 Oct 2025
Viewed by 1295
Abstract
Background/Objectives: Whole-gland surgery or radiotherapy for localized prostate cancer (PCa) can cure the disease but often impair urinary and sexual function. Focal therapy with high-intensity focused ultrasound (HIFU) seeks to eradicate the tumor while sparing uninvolved tissue. We prospectively evaluated oncological control, [...] Read more.
Background/Objectives: Whole-gland surgery or radiotherapy for localized prostate cancer (PCa) can cure the disease but often impair urinary and sexual function. Focal therapy with high-intensity focused ultrasound (HIFU) seeks to eradicate the tumor while sparing uninvolved tissue. We prospectively evaluated oncological control, functional outcomes and safety of MRI-guided focal HIFU in patients with low- or intermediate-risk PCa. Methods: In this prospective, single-arm, phase II feasibility trial (three Austrian centres, 2021–2024), treatment-naive patients with D’Amico low/intermediate-risk, PSA ≤ 15 ng/mL, clinical stage ≤ T2 and MRI-targeted, biopsy-confirmed index lesions underwent lesion-targeted HIFU (Focal One™). The primary endpoint was failure-free survival (FFS: absence of salvage whole-gland or systemic therapy, metastasis or PCa-specific death). Secondary endpoints included biopsy-proven cancer, prostate-specific antigen (PSA), patient-reported symptoms as International Prostate Symptom Score (IPSS), 5-item International Index of Erectile Function (IIEF), Gaudenz Incontinence Questionnaire and adverse events. Planned follow-up was 24 months with PSA every 3 months, mpMRI and biopsies at 12 months, and imaging- or PSA-triggered biopsies thereafter. Results: Fifty-one men were analysed in the per-protocol cohort (median age 67 years, median PSA 7.55 ng/mL). Median treated volume was 12 mL; median procedure time 85 min. At 24 months, FFS was 94.1%: 3/51 patients (5.9%) required salvage radiotherapy. Among 31 patients who underwent follow-up biopsy, 26 (83.9%) had no cancer; the five positives included three ISUP 1, one ISUP2 and one ISUP 4 lesion. Mean PSA fell by 69% at 3 months (to 2.3 ng/mL) and then stabilized under 3 ng/mL, with a mean of 2.7 ± 1.5 ng/mL at 24 months. Transient acute urinary retention occurred in 11/51 (21.6%); no Clavien–Dindo grade ≥ 4 events were reported. IPSS returned to or improved beyond baseline, erectile function largely recovered by 6–12 months, and only one new case of grade 2 incontinence was observed. Conclusions: MRI-guided focal HIFU achieved high two-year failure-free survival with low morbidity and preserved quality of life in carefully selected patients with low- or intermediate-risk PCa. These data support further randomized and longer-term investigations of focal HIFU as an organ-sparing alternative to whole-gland treatment. Full article
(This article belongs to the Special Issue Contemporary Diagnosis and Management of Prostate Cancer (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop